Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model.

Haruaki NoboriKeita FukaoTakayuki KurodaNaomi AnanRyoichi TashimaMasaaki NakashimaSayuri NodaMinako TajiriMikinori ToriiShinsuke TobaKentaro UemuraTakao SanakiTakao ShishidoYuki Tachibana Teruhisa Kato

Published in: The Journal of antimicrobial chemotherapy (2022)

This was the first evaluation of the in vivo anti-SARS-CoV-2 efficacy of ensitrelvir in a delayed-treatment mouse model. In this model, ensitrelvir demonstrated high antiviral potential and suppressed lung inflammation and lethality caused by SARS-CoV-2 infection. The findings support the continued clinical development of ensitrelvir as an antiviral agent to treat patients with COVID-19.

Keyphrases

sars cov
mouse model
respiratory syndrome coronavirus
oxidative stress